No Data
No Data
BioNTech SE's BNT327 Shows Promising Results in SCLC, Earning a Buy Rating From Analyst
European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading
Crisis and Redemption: The Darkest Moment and Dawn of the Vaccine Industry.
The vaccine Industry is currently facing challenges, but its fate is not simply a one-way decline.
CCORF Maintains BioNTech(BNTX.US) With Buy Rating, Cuts Target Price to $171
Goldman Sachs Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $136
Berenberg Bank Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $130